This document includes key elements to be considered in the risk-based decision-making process of mitigating the threats to the safety of substances of human origin posed by Zika virus.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Two developments in the field of variant Creutzfeldt–Jakob disease (vCJD) occurred in 2009. In order to address a number of questions that were raised, ECDC internal and external experts prepared this risk assessment. The document focuses on how these new facts affect the current assumptions regarding transmissibility of the disease through blood transfusion and tissue/cells transplantation.